Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and treatment experience of participants prescribed BRIUMVI4 ublituximab-xiiy for relapsing multiple sclerosis RMS in a real-world setting. The study aims to gather insights over time on how this treatment works outside of controlled clinical trials. Participants will receive BRIUMVI4 ublituximab-xiiy through intravenous infusion as part of their routine care for RMS. This observational study follows these participants longitudinally to monitor their health and treatment experience without assigning any new interventions. During the study, participants will be monitored for relapses, adverse events, and infusion-related reactions up to 96 weeks. Researchers will collect data from medical records and routine visits to assess annualized relapse rates and safety outcomes, supporting a comprehensive understanding of treatment effects in everyday clinical practice. The study duration extends until 2032, allowing for long-term follow-up.
Actively Recruiting
Researchers are evaluating the use of Vedolizumab in adults with moderate to severely active Ulcerative Colitis UC or Crohns Disease CD. These long-term gut conditions cause symptoms like diarrhea, inflammation, bleeding, and belly pain. The study aims to determine how many participants achieve remission, meaning their symptoms disappear, after 14 weeks of treatment. This is a Phase 4 treatment study sponsored by Takeda. Participants will receive Vedolizumab through two methods. For the first 6 weeks, they get 300 mg intravenously at weeks 0 and 2, with a possible additional dose at week 6. Afterward, starting by week 6 and definitely by week 14, the administration switches to 108 mg injections under the skin every 2 weeks until week 50. Participants who do not respond to treatment by week 14 will stop Vedolizumab and may switch to other treatments, with additional clinic visits at 26 and 52 weeks. A follow-up occurs 18 weeks after the last Vedolizumab dose. Throughout the study, participants have several clinic visits for treatments and assessments. Researchers will measure remission rates using patient-reported outcomes at weeks 6, 14, and 52, alongside clinical response, endoscopic results, and markers like C-reactive protein and fecal calprotectin. Safety is monitored by tracking serious infections up to 72 weeks. The total participation time spans about one year of treatment plus follow-up after treatment ends.
Actively Recruiting
Researchers are evaluating the safety and effects of the study medicine PF-07248144 combined with fulvestrant for treating hormone receptor-positive HR-positive, HER2-negative advanced or metastatic breast cancer. This study focuses on patients whose cancer has progressed after prior treatment with cyclin dependent kinase CDK 46 inhibitor-based therapy. HR-positive breast cancer cells grow in response to hormones like estrogen and progesterone, while HER2-negative cells have little or no HER2 protein, which affects cancer growth and spread. Participants are divided into two groups one receives PF-07248144 tablets daily at home in 28-day cycles along with fulvestrant injections given at the clinic. The other group receives everolimus tablets daily combined with the investigators choice of endocrine therapy, either exemestane tablets or fulvestrant injections. The study compares the safety and effects of PF-07248144 plus fulvestrant against these standard treatments. During the study, participants will have regular clinic visits for injections and monitoring. Researchers will assess disease progression and survival, measure tumor response, record any side effects, and perform laboratory tests including ECGs and drug level checks. The main outcome is progression-free survival, tracked for up to two years, while other safety and effectiveness measures will be followed for up to five years. Total participation may extend over several years depending on individual outcomes.
Actively Recruiting
Adolescents in residential substance use treatment often face serious substance-related challenges and high relapse rates, with studies showing that 60% relapse within 90 days after discharge. Parenting practices play a key role in influencing adolescent substance use outcomes, yet engaging parents in treatment has historically been difficult. This research evaluates a technology-assisted parenting program called Parent SMART, designed to support parents and improve adolescent outcomes during and after residential treatment. Parent SMART combines an existing computer-based parenting skills program called Parenting Wisely with up to four telehealth coaching sessions and an app-based networking forum where parents can connect with experts and other parents. The study compares adolescents receiving standard residential treatment alone to those whose parents receive Parent SMART alongside usual care. Parent SMART sessions are delivered by counselors, and the program is offered both during short and long residential stays, with the goal of enhancing parental monitoring and communication. Participants include adolescent-parent pairs who will be randomly assigned to either standard treatment or Parent SMART plus treatment. Follow-up assessments occur at 6, 12, and 24 weeks after discharge, including self-reports, videotaped interactions, and urine screenings. The study measures changes in parenting behaviors, adolescent substance use, and related high-risk behaviors over 24 weeks. The results aim to show whether Parent SMART improves parenting and reduces adolescent substance use and related problems after residential treatment.
Actively Recruiting
Researchers are evaluating a modified regimen of ublituximab for adults with relapsing multiple sclerosis RMS in this phase 3b study. The study aims to assess the medicines impact on brain lesions visible on MRI scans and its pharmacokinetics, particularly in participants who had limited benefit from prior anti-CD20 therapies. The trial includes three parts Part A is open-label and single-arm, Part B is randomized, double-blind, and placebo-controlled, and Part C is open-label and single-arm. Participants receive ublituximab through intravenous infusions, with dosing schedules varying by study part. In Part A, infusions occur on Day 1 of Week 1, Day 15 if applicable, and at Week 24. In Part B, participants receive either 600 mg ublituximab on Week 1 Day 1, placebo on Day 15, and 450 mg ublituximab at Week 24, or 150 mg ublituximab on Week 1 Day 1 followed by 450 mg on Day 15 and Week 24. Part C participants receive 150 mg on Week 1 Day 1 and 450 mg on Day 15 and Week 24. During the study, participants are monitored for changes in T1 Gadolinium-enhancing lesions on MRI from baseline to Week 48, infusion-related reactions, treatment satisfaction, and pharmacokinetics over 16 weeks. Safety and efficacy assessments include neurological stability, clinical exams, and questionnaires. The total study duration extends to at least 48 weeks, with detailed follow-up and monitoring to evaluate treatment impact and participant health.
Actively Recruiting
Researchers are evaluating the safety and remyelinating effects of the SetPoint System, a miniaturized stimulator implanted on the vagus nerve, in adults with relapsing-remitting multiple sclerosis RRMS. This pilot study compares active stimulation to non-active stimulation while participants continue their standard disease-modifying therapies. The study aims to understand the devices potential as an adjunctive treatment alongside current RRMS care. Participants will undergo surgery under general anesthesia to implant the device on the left side of the neck. Following implantation, two-thirds of participants receive active stimulation for one minute once daily, while one-third receive non-active stimulation for the same duration. After 48 weeks, control group participants will switch to active stimulation, and all participants will continue active stimulation during a 48-week open-label follow-up to assess long-term safety. During the study, participants will be monitored for adverse events from consent through 96 weeks. Evaluations include standard clinical assessments and imaging to track disease activity. The trial involves regular visits for treatment delivery and safety monitoring, with blinding maintained until week 48 assessments are complete. Total participation lasts approximately 96 weeks, including treatment and follow-up periods.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the use of a non-invasive cryo-compression therapy to improve pain control after arthroscopic rotator cuff surgery. This study compares this novel method to standard ice wraps in managing post-operative pain, swelling, opioid use, and quality of life. The trial aims to provide evidence that could influence pain management practices in orthopedic surgery, addressing concerns about opioid use. Participants are randomly assigned to one of two groups one using the intermittent cryo-compression device called the NICE Recovery SystemTM, and the other using standard gel ice packs with wraps. The cryo-compression group receives a compression sleeve applied immediately after surgery with programmed compression and cooling settings, aiming for at least 6 hours of treatment daily. The control group uses gel ice packs with the same daily duration. Both groups follow a detailed post-operative care plan. Participants will complete pre-operative data collection and maintain a diary to record pain and therapy use until the first post-operative visit. Follow-up visits are scheduled at 2 days, 1 visit shortly after, 60 days, 3 months, 6 months, and 12 months post-surgery. Researchers will assess pain using the Visual Analog Scale, measure arm swelling, analyze costs, and evaluate quality of life over one year. This thorough monitoring aims to capture differences in recovery and patient experience between the two cryotherapy methods.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of VE303, a live biotherapeutic product, in preventing the recurrence of Clostridioides difficile infection CDI. This study focuses on participants with either recurrent CDI or primary CDI at high risk for recurrence, assessing the recurrence rate at 8 weeks after treatment. The study is a randomized, double-blind, placebo-controlled Phase 3 trial sponsored by Vedanta Biosciences, Inc. Participants receive either VE303 or a matching placebo after completing 10 to 21 days of standard antibiotic treatment for their CDI episode. Those assigned to the VE303 group take 3 capsules daily for 14 days the placebo group takes 3 placebo capsules daily for the same duration. The capsules look identical to ensure blinding. This treatment period follows the completion of their initial antibiotic therapy. Throughout the study, participants are monitored for CDI recurrence up to 8 weeks after treatment. Researchers evaluate safety and measure the rate of CDI coming back during this period. Participants must have completed standard antibiotic therapy and meet clinical stability criteria before starting the study drug. The total participation time includes screening, treatment, and observation phases until the primary outcome at week 8 is assessed.